{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T08:56:12Z","timestamp":1765529772427,"version":"3.48.0"},"reference-count":26,"publisher":"Walter de Gruyter GmbH","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Over time, it became evident that with the use of micronized progesterone and dydrogesterone prevention or treatment of pregnancy disorders such as threatened miscarriage, recurrent (habitual) miscarriage, preterm labor or preeclampsia appears to be possible. The results so far obtained will be delineated and concepts of prevention or treatment are suggested with the aim to further explore these pregnancy disorders either by prevention or treatment concepts to obtain not only benefits to the mother and the fetus, but furthermore this results in benefits for lifetime for the individual, for the family and last but not least for society.<\/jats:p>","DOI":"10.1515\/hmbci-2016-0028","type":"journal-article","created":{"date-parts":[[2016,9,23]],"date-time":"2016-09-23T05:01:29Z","timestamp":1474606889000},"page":"49-53","source":"Crossref","is-referenced-by-count":10,"title":["Present and future aspects of dydrogesterone in prevention or treatment of pregnancy disorders: an outlook"],"prefix":"10.1515","volume":"27","author":[{"given":"Adolf E.","family":"Schindler","sequence":"first","affiliation":[{"name":"Institute for Medical Research and Education, University Clinic, SHH1, Appt. 0809, Hufelandstrasse 55, D-45122 Essen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2016,9,23]]},"reference":[{"key":"2025121207303713745_j_hmbci-2016-0028_ref_001_w2aab3b8c13b1b7b1ab2ab1Aa","doi-asserted-by":"crossref","unstructured":"Schindler AE. First trimester endocrinology. Consequences for diagnosis and treatment of pregnancy failures. Gynecol Endocrinol 2004;18:51\u20137.","DOI":"10.1080\/09513590310001651795"},{"key":"2025121207303713745_j_hmbci-2016-0028_ref_002_w2aab3b8c13b1b7b1ab2ab2Aa","doi-asserted-by":"crossref","unstructured":"Csapo AI, Pulkinen MO, Ruttner B, Sauvage JP, Wiest WG. The significance of the human corpus luteum in pregnancy maintenance. Am J Obstet Gynecol 1972;112:1061\u20137.","DOI":"10.1016\/0002-9378(72)90181-0"},{"key":"2025121207303713745_j_hmbci-2016-0028_ref_003_w2aab3b8c13b1b7b1ab2ab3Aa","doi-asserted-by":"crossref","unstructured":"McCord ML, Arheart KL, Muram D, Stovall TG, Buster JE, Carson SE. Single serum progesterone as a screen for ectopic pregnancy, enhancing specificity and sensitivity to obtain optimal test performance. Fert Steril 1996;66:513\u20136.","DOI":"10.1016\/S0015-0282(16)58560-4"},{"key":"2025121207303713745_j_hmbci-2016-0028_ref_004_w2aab3b8c13b1b7b1ab2ab4Aa","doi-asserted-by":"crossref","unstructured":"Carp H. A systematic review of dydrogesterone for the treatment of threatened miscarriage. Gynecol Endocrinol 2012;28:983\u201390.","DOI":"10.3109\/09513590.2012.702875"},{"key":"2025121207303713745_j_hmbci-2016-0028_ref_005_w2aab3b8c13b1b7b1ab2ab5Aa","doi-asserted-by":"crossref","unstructured":"Schindler AE, Carp H, Druckmann R, Genazzani AR, Huber J, Pasqualini J, Schweppe KW, Szekeres-Bartho J. Guidelines of the European Progestogen Club for treatment or prevention of threatened or recurrent (habitual) miscarriage. Gynecol Endocrinol 2015;15:447\u20139.","DOI":"10.3109\/09513590.2015.1017459"},{"key":"2025121207303713745_j_hmbci-2016-0028_ref_006_w2aab3b8c13b1b7b1ab2ab6Aa","doi-asserted-by":"crossref","unstructured":"Wahabi HA, Fayed AA, Esmail SA, Elawad M. Progestogen for treating threatened miscarriage. Cochrane Data Base Syst Rev 2011;12:CD005943.","DOI":"10.1002\/14651858.CD005943.pub3"},{"key":"2025121207303713745_j_hmbci-2016-0028_ref_007_w2aab3b8c13b1b7b1ab2ab7Aa","doi-asserted-by":"crossref","unstructured":"Saraswat L, Bhattacharya S, Maheshwan A, Bhattacharya S. Maternal and perinatal outcome in women with threatened miscarriage in the first trimester: a systematic review. Br J Obstet Gynaecol 2010;117:245\u201357.","DOI":"10.1111\/j.1471-0528.2009.02427.x"},{"key":"2025121207303713745_j_hmbci-2016-0028_ref_008_w2aab3b8c13b1b7b1ab2ab8Aa","doi-asserted-by":"crossref","unstructured":"Jauniaux E, Vav Oppenraaji RH, Burton GJ. Obstetric outcome after early placental complications. Curr Opin Obstet Gynecol 2010;22:452\u20137.","DOI":"10.1097\/GCO.0b013e3283404e44"},{"key":"2025121207303713745_j_hmbci-2016-0028_ref_009_w2aab3b8c13b1b7b1ab2ab9Aa","doi-asserted-by":"crossref","unstructured":"Ahmed SR, El-Sammani M, Al-Sheeha MA, Aitallah AS, Jabin Khan F, Ahmed SR. Pregnancy outcome in women with threatened miscarriage: a year study. Mat Soc Med 2012;24:26\u20138.","DOI":"10.5455\/msm.2012.24.26-28"},{"key":"2025121207303713745_j_hmbci-2016-0028_ref_010_w2aab3b8c13b1b7b1ab2ac10Aa","doi-asserted-by":"crossref","unstructured":"Salazar El, Calzada L. The role of progesterone in endometrial estradiol- and progesterone receptor synthesis in women with menstrual disorders and habitual abortion. Gynecol Endocrinol 2007;23:222\u20135.","DOI":"10.1080\/09513590701254030"},{"key":"2025121207303713745_j_hmbci-2016-0028_ref_011_w2aab3b8c13b1b7b1ab2ac11Aa","doi-asserted-by":"crossref","unstructured":"Coomarasamy A, Williams H, Truchanowicz E, Seed PT, Small R, Quenby S, Gupta P, Dawood F, Koot YE, Bender Atik R, Bloemenkamp KW, Brady R, Briley AL, Cavallaro R, Cheong YC, Chu JJ, Eapen A, Ewies A, Hoek A, Kaaijk EM, Koks CA, Li TC, MacLean M, Mol BW, Moore J, Ross JA, Sharpe L, Stewart J, Vaithilingam N, Farquharson RG, Kilby MD, Khalaf Y, Goddijn M, Regan L, Rai R. A randomized trial of progesterone in women with recurrent miscarriages. N Engl J Med 2015;373:2141\u20138.","DOI":"10.1056\/NEJMoa1504927"},{"key":"2025121207303713745_j_hmbci-2016-0028_ref_012_w2aab3b8c13b1b7b1ab2ac12Aa","doi-asserted-by":"crossref","unstructured":"Kumar A, Beguin N, Prasat S, Aggarwal S, Sharma SH. Oral dydrogesterone treatment during early pregnancy to prevent recurrent pregnancy loss and its role in modulation of cytokine production: a double-blind, randomized, placebo-controlled trial. Fert Steril 2014;102:1354\u20137.","DOI":"10.1016\/j.fertnstert.2014.07.1251"},{"key":"2025121207303713745_j_hmbci-2016-0028_ref_013_w2aab3b8c13b1b7b1ab2ac13Aa","doi-asserted-by":"crossref","unstructured":"Ghosh S, Chattopadhyay R, Goswani S, Chaudhury K, Chakravarty B, Ganesh A. Assessment of sub-endometrial blood flow parameters following dydrogesterone and micronized vaginal progesterone administration in women with idiopathic recurrent miscarriage: a pilot study. J Obstet Gynaecol Res 2014;40:1871\u20136.","DOI":"10.1111\/jog.12456"},{"key":"2025121207303713745_j_hmbci-2016-0028_ref_014_w2aab3b8c13b1b7b1ab2ac14Aa","doi-asserted-by":"crossref","unstructured":"Carp H. A systematic review of dydrogesterone for the treatment of recurrent miscarriage. Gynecol Endocrinol 2015;31:422\u201330.","DOI":"10.3109\/09513590.2015.1006618"},{"key":"2025121207303713745_j_hmbci-2016-0028_ref_015_w2aab3b8c13b1b7b1ab2ac15Aa","doi-asserted-by":"crossref","unstructured":"Armstrong J. 17-Progesterone for preterm birth prevention: a potential US\u00a7 2 billion opportunity. Am J Obstet Gynecol 2007;196:194\u20135.","DOI":"10.1016\/j.ajog.2006.12.022"},{"key":"2025121207303713745_j_hmbci-2016-0028_ref_016_w2aab3b8c13b1b7b1ab2ac16Aa","doi-asserted-by":"crossref","unstructured":"Da Fonseca EB, Bittar RE, Carvalho MH, Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol 2003;188:419\u201324.","DOI":"10.1067\/mob.2003.41"},{"key":"2025121207303713745_j_hmbci-2016-0028_ref_017_w2aab3b8c13b1b7b1ab2ac17Aa","doi-asserted-by":"crossref","unstructured":"Schindler AE. Progestogens for treatment and prevention of pregnancy disorders. Horm Mol Biol Clin Invest 2010;3:453\u201360.","DOI":"10.1515\/HMBCI.2010.069"},{"key":"2025121207303713745_j_hmbci-2016-0028_ref_018_w2aab3b8c13b1b7b1ab2ac18Aa","doi-asserted-by":"crossref","unstructured":"Keirse MJ. Progestogen administration in pregnancy may prevent preterm delivery. Br J Obstet Gynecol 1990;9:149\u201354.","DOI":"10.1111\/j.1471-0528.1990.tb01740.x"},{"key":"2025121207303713745_j_hmbci-2016-0028_ref_019_w2aab3b8c13b1b7b1ab2ac19Aa","doi-asserted-by":"crossref","unstructured":"Romero R, Nicoleides K, Conde-Agudelo A, Tabor A, O\u02bcBrien JM, Cetingoz E, Da Fonseca E, Creasy GW, Klein K, Rode L, Soma-Pillay P, Fusey S, Cam C, Alfirevic Z, Hassan SS. Vaginal progesterone in women with an asymptomatic sonographic short cervix in the midtrimester decreases preterm delivery and neonatal morbidity: a systematic review and metaanalysis of individual based data. Am J Obstet Gynecol 2012;206:124e1\u201319.","DOI":"10.1016\/j.ajog.2011.12.003"},{"key":"2025121207303713745_j_hmbci-2016-0028_ref_020_w2aab3b8c13b1b7b1ab2ac20Aa","doi-asserted-by":"crossref","unstructured":"Gonzalez-Quintero VH, Cordova YC, Istwan NB, Tudela F, Rhea DJ, Romary LM, Marimon A, Desch CN, Stanziano GJ. Influence of gestational age and reason for prior preterm birth on rates of recurrent preterm delivery. Am J Obstet Gynecol 2011;205:275\u20139.","DOI":"10.1016\/j.ajog.2011.06.043"},{"key":"2025121207303713745_j_hmbci-2016-0028_ref_021_w2aab3b8c13b1b7b1ab2ac21Aa","doi-asserted-by":"crossref","unstructured":"Khashani AS, McNamee R, Abel KM. Rates of preterm birth for antenatal exposure to score life events: a population-based cohort study. Hum Reprod 2009;24:429\u201337.","DOI":"10.1093\/humrep\/den418"},{"key":"2025121207303713745_j_hmbci-2016-0028_ref_022_w2aab3b8c13b1b7b1ab2ac22Aa","doi-asserted-by":"crossref","unstructured":"Blois SM, Joachim R, Kandil J, Margni R, Tometten M, Klapp BF, Arck PC. Depletion of CD8+ cells abolishes the pregnancy protective effect of progesterone substitution with dydrogesterone in mice by altering the Th1\/Th2 cytokine profile. J Immunol 2004;172:5893\u20139.","DOI":"10.4049\/jimmunol.172.10.5893"},{"key":"2025121207303713745_j_hmbci-2016-0028_ref_023_w2aab3b8c13b1b7b1ab2ac23Aa","doi-asserted-by":"crossref","unstructured":"Hudic H, Skekeres-Bartho J, Fatusic Z, Stray-Pedersen B, Dizdarevi\u0107-Hudi\u0107 L, Latifagi\u0107 A, Hoti\u0107 N, Kameri\u0107 L, Mand\u017ei\u0107 A. Dydrogesterone supplementation in women with threatened preterm delivery \u2013 the impact on cytokine profile, hormone profile and progesterone induced blocking factor. J Reprod Immunol 2011;92:103\u20137.","DOI":"10.1016\/j.jri.2011.08.006"},{"key":"2025121207303713745_j_hmbci-2016-0028_ref_024_w2aab3b8c13b1b7b1ab2ac24Aa","unstructured":"Ragab MI, Sammour MB, ElKabarity H, Hegazy MR. Progesterone: a treatment for preeclamptic toxaemia. Ain Shams Med J 1971;22:9\u201324."},{"key":"2025121207303713745_j_hmbci-2016-0028_ref_025_w2aab3b8c13b1b7b1ab2ac25Aa","doi-asserted-by":"crossref","unstructured":"Sammour MB, El Makhzangy MN, Fawzy MM, Schindler A. Progesterone therapy in pregnancy induced hypertension: therapeutic value and hormonal profile. Clin Exp Hypertens B 1982;1:475\u20138.","DOI":"10.3109\/10641958209009619"},{"key":"2025121207303713745_j_hmbci-2016-0028_ref_026_w2aab3b8c13b1b7b1ab2ac26Aa","doi-asserted-by":"crossref","unstructured":"Zainul RM, Lim JF, Nawaun NH, Luqman M, Zolkeplai MF, Rangkuty HS, Mohamd Nor NA, Tamil A, Shah SA, Tham SW, Schindler AE. A pilot study to determine whether progestogen supplementation using dydrogesterone during the first trimester will reduce the incidence of gestational hypertension in pregnancy. Gynecol Endocrinol 2014;30:217\u201320.","DOI":"10.3109\/09513590.2013.860960"}],"container-title":["Hormone Molecular Biology and Clinical Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/hmbci.2016.27.issue-2\/hmbci-2016-0028\/hmbci-2016-0028.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/hmbci-2016-0028\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/hmbci-2016-0028\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T08:51:08Z","timestamp":1765529468000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/hmbci-2016-0028\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,1]]},"references-count":26,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,9,23]]},"published-print":{"date-parts":[[2016,8,1]]}},"alternative-id":["10.1515\/hmbci-2016-0028"],"URL":"https:\/\/doi.org\/10.1515\/hmbci-2016-0028","relation":{},"ISSN":["1868-1891","1868-1883"],"issn-type":[{"type":"electronic","value":"1868-1891"},{"type":"print","value":"1868-1883"}],"subject":[],"published":{"date-parts":[[2016,8,1]]}}}